Amarin Corporation PLC (NASDAQ:AMRN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued on Thursday. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 212.50% from the stock’s current price.

A number of other equities analysts also recently weighed in on the company. Zacks Investment Research upgraded Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Monday, July 3rd. BidaskClub downgraded Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research note on Saturday, August 5th. Jefferies Group LLC started coverage on Amarin Corporation PLC in a research note on Thursday, June 29th. They issued a “reduce” rating and a $3.50 target price on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research note on Thursday, June 1st. Finally, ValuEngine upgraded Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research note on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $7.35.

Shares of Amarin Corporation PLC (NASDAQ AMRN) traded up 6.56% during trading on Thursday, hitting $3.41. The stock had a trading volume of 2,012,479 shares. The company’s market capitalization is $923.40 million. Amarin Corporation PLC has a 52 week low of $2.56 and a 52 week high of $4.47. The company’s 50 day moving average price is $3.34 and its 200 day moving average price is $3.31.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $44.95 million during the quarter, compared to analysts’ expectations of $40.35 million. During the same quarter in the previous year, the firm earned ($0.07) EPS. Amarin Corporation PLC’s quarterly revenue was up 37.0% on a year-over-year basis. Analysts predict that Amarin Corporation PLC will post ($0.21) earnings per share for the current year.

WARNING: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/amarin-corporation-plc-amrn-receives-overweight-rating-from-cantor-fitzgerald.html.

In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of the stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total transaction of $1,231,644.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 3.72% of the company’s stock.

Several large investors have recently bought and sold shares of the business. Westside Investment Management Inc. increased its holdings in shares of Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 300 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 1,500 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 7,580 shares during the period. Perkins Capital Management Inc. increased its holdings in shares of Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 7,000 shares during the period. Finally, Private Advisor Group LLC increased its holdings in shares of Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 1,032 shares during the period. Hedge funds and other institutional investors own 37.76% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.